Bicyclic and tricyclic compounds as KAT II inhibitors
申请人:Pfizer Inc.
公开号:US08183238B2
公开(公告)日:2012-05-22
Compounds of Formula X:
wherein A, X, Y, Z, R5, R6a, and R6b are as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other neurodegenerative and/or neurological disorders in mammals, including humans.